Abstract
engineered T cells. Transferred CD4 + T cells had to be antigen-specific (not just activated) and secrete IFN-γ to potentiate the anti-tumor effect. Importantly, antitumor responses in these mice correlated with localisation and persistence of geneengineered T cells at the tumor site. Strikingly, mice that survived primary tumor challenge could reject a subsequent rechallenge. Overall, this study has highlighted the therapeutic potential of using combined transfer of antigen-specific gene-modified CD8 + and CD4 + T cells to significantly enhance T cell adoptive transfer strategies for cancer therapy.
Introduction
Much attention has been directed at the genetic modification of T cells and their therapeutic potential in the adoptive immunotherapy of cancer. T cells engineered to express chimeric surface receptors that incorporate an extracellular single-chain antibody domain (scFv) and a transmembrane and cytoplasmic signaling domain can specifically direct anti-tumor immune responses in a MHC-independent manner at targets normally capable of evading immune recognition. These targets also often lack important co-stimulatory ligands for maximal T cell activation. The therapeutic potential of engineered T cells extends from studies demonstrating specific antigen binding and target cell lysis in vitro [1] [2] [3] and in a range of different mouse tumor models [4] [5] [6] [7] [8] to their successful transfer into patients with minimal side effects in Phase I clinical trials 9 .
There have been a number of studies demonstrating the importance of CD4 + T cell help in elimination of infectious disease and for anti-tumor immunity 10, 11 . CD4 + T cells have been demonstrated to be critical for maintainence of CD8 + T cell numbers, their recruitment to the tumor site [12] [13] [14] and for induction of a memory response 15, 16 .
In patients infected with human immunodeficiency virus, the co-infusion of genetically modified CD4 + and CD8 + T cells has been demonstrated to overcome the lack of T cell persistence observed with transfusion of engineered CD8 + T cells alone 9, 17 . However, despite these promising studies, the issue of whether the addition of antigen-specific engineered CD4 + T cell help may enhance anti-tumor immunity, long-term persistence and secondary tumor rejection has not been properly tested in vivo for adoptively transferred T cells. 
Materials and Methods

Cell Culture
MDA-MB-435 human mammary carcinoma cells, the erbB2-expressing MDA-MB-435 cells, 4T1.2 mouse mammary carcinoma cells and the erbB2-expressing 4T1.2-erbB2 cells were cultured in DMEM supplemented with 10% (v/v) FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies, Grand Island, NY). Retrovirus-producing GP+E86 cells were cultured in DMEM containing 0.5 mg/ml G418 (Life Technologies). 
Mice
Generation of scFv-receptor transduced CD8
+ and CD4 + mouse T cells A chimeric gene construct composed of the scFv-anti-erbB2 monoclonal antibody (mAb), a membrane proximal hinge region of human CD8, and the transmembrane and cytoplasmic regions of the mouse CD28 signaling chain fused to the cytoplasmic region of human TCR-ζ (scFv-anti-erbB2-CD28-ζ) was cloned into the retroviral vector pLXSN as previously described 5 . A stable GP+E86 ecotrophic packaging cell line expressing the scFv-anti-erbB2-CD28-ζ receptor was isolated as previously described 5 . Transduction of mouse splenic T lymphocytes was performed as described previously 7, 18 . To generate transduced CD8 + and CD4 + T cells each T cell 
Flow Cytometry
Expression of the α-erbB2-CD28-ζ chimeric receptor on the surface of CD8 + , CD4 + or unfractionated transduced mouse T cells was determined by indirect immunofluorescence with a c-myc tag Ab, followed by staining with a PE-labeled anti-mouse Ig mAb (BD Biosciences, San Jose, CA). Background fluorescence was assessed using the PE-labeled anti-mouse Ig mAb alone. Cell surface phenotyping of transduced cells was determined by direct staining with FITC-labeled anti-CD4 (RM4-5; PharMingen) and PE-labeled anti-CD8 (53-6.7; PharMingen) mAbs, as previously described 4, 5, 7, 18 .
Antigen-specific cytotoxicity, cytokine secretion and proliferation by transduced T cells
The ability of transduced T cells to specifically mediate target cell lysis was assessed in a 6 h chromium release assay, as described previously 19 . The capacity of transduced T cells to produce cytokines (IFN-γ, IL-2, GM-CSF, IL-4) after erbB2 antigen ligation was determined by enzyme-linked immunosorbent assay (ELISA) (PharMingen) and the proliferative capacity of transduced T cells was assessed in a [ 3 H]-thymidine incorporation assay, as described previously 3, 5 .
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Immunohistochemistry
Hematoxylin/Eosin staining and immunohistochemistry were performed on frozen sections. Antibodies used were FITC-anti-mouse CD4, biotin-anti-mouse CD8b.2, APC-anti-mouse CD11b, FITC-anti-mouse CD11b (all from Becton Dickenson), biotin-anti-myc tag (Abcam), isotype controls and a streptavidin Alexa 594 secondary (Molecular Probes).
Polymerase chain reaction (PCR)
The detection of gene-engineered T cells following adoptive transfer in mice was assessed by PCR amplification of the neomycin phosphotransferase gene. Mice from either BALB/c-wildtype or BALB/c IFN-γ -/-donor mice were used to evaluate the role of IFN-γ released by either T cell subset in the anti-tumor effect. All mice were monitored daily for tumor growth. Tumor growth was assessed as follows; (1) in survival experiments, mice that were morbid were sacrificed and the day of death and lung weights recorded or (2) mice were sacrificed at days 6, 12 or 16 and harvested lungs were fixed in 10% formalin, embedded, sectioned and stained with H & E for histological examination or frozen sections of lungs were made for immunohistochemical analysis.
Tumor rechallenge experiments
Mice long term surviving the primary MDA-MB-435 tumor (>100 days) were rechallenged with an i.v. injection of 5 x 10 6 human MDA-MB-435-erbB2 tumor cells Figure   1A and B) 4, 5, 7, 18 . To determine whether we could achieve expression of the chimeric α-erbB2-CD28-ζ receptor in a greater percentage of CD4 + T cells, CD8 + and CD4 + T cells were isolated by magnetic bead depletion prior to transduction. Using this approach, we were able to achieve good levels of expression of the chimeric α-erbB2-CD28-ζ receptor in CD8 + and CD4 + T cells after staining with a c-myc anti-tag antibody ( Figure 1D 
Transduced CD8 + and CD4 + mouse T cells mediate antigen-specific cytokine secretion, proliferation and tumor cell lysis
The functional capacity of either unfractionated, CD4 + or CD8 + transduced T cells was compared in a number of different in vitro assays. We have previously shown the ability of scFv-CD28-ζ unfractionated engineered T cells to secrete Tc1 cytokines (IFN-γ and GM-CSF) upon antigen stimulation with erbB2 + target cells 5, 6 . Thus, it was of interest to Figure 3B ).
In addition, mice receiving a 1:1 ratio of transduced CD8 + and CD4 + T cells of irrelevant specificity or no T cells did not survive ( Figure 3A) . Interestingly, no anti-tumor effect was observed in mice that received either 10 7 transduced CD4 + or CD8 + T cells alone indicating a requirement for co-operation of the two types of T cell against such established tumors ( Figure 3A) . In another experiment, increasing the dose by administering two injections of 10 7 gene-engineered CD8 + T cells alone at days 5 and 6 resulted in improved survival of a small number of mice ( Figure 3C ). However, mice receiving both engineered CD8 + and CD4 + T cells at a 1:1 ratio at just a single dose again resulted in 100% survival. Thus, clearly in our model, optimal anti-tumor effects were observed by inclusion of engineered CD4 + T cells in the treatment regimen. In these experiments, it may have been likely that 5 day established tumor was too advanced for transduced CD8 + T cells to exert an effective anti-tumor effect which is consistent with other adoptive transfer studies involving antigen-specific CD8 + T cells 14, 22 .
To determine the optimal ratio of scFv-CD28-ζ transduced CD4 + and CD8 + T cells required to achieve 100% survival, mice bearing 5 day MDA-MB-435-erbB2 tumor were treated with different ratios of scFv-CD28-ζ transduced CD8 + and CD4 + T cells.
Interestingly, only a 1:1 ratio of transduced CD8 + and CD4 + T cells (5 x 10 6 of each T cell subset) resulted in 100% survival consistent with previous experiments ( Figure 3D ).
In contrast, the percentage of survivors decreased significantly when mice received a greater proportion of either CD8 + or CD4 + transduced T cells ( Figure 3D) . Collectively, these results demonstrated for the first time in vivo that optimal transfer of engineered Figure 5H and L). Interestingly, neither transduced CD8 + or CD4 + T cells injected alone were detected in d16 lung sections, consistent with no anti-tumor effect observed in these mice (data not shown). As controls, both CD8 + and CD4 + T cells were detected in spleens of BALB/c mice using the same immunohistochemical staining procedure, but not in lungs from normal scid mice (data not shown).
For 
Antigen-specific response to tumor rechallenge
An important issue with regard to any cancer therapy is whether the specific treatment can induce a secondary response to tumor relapse. To test whether our scFv approach could effectively mediate a response to secondary tumor rechallenge, long term surviving mice (>100 days) initially treated with transduced CD8 + and CD4 + T cells were injected with an i.v. dose of 5x10 6 MDA-MB-435-erbB2 tumor cells. Remarkably, all mice were able to totally eradicate a second dose of MDA-MB-435-erbB2 tumor ( Figure 6A ).
Normal scid mice injected with MDA-MB-435-erbB2 cells did not survive ( Figure 6A ).
As a further test of specificity, long-term surviving mice were rechallenged with a subcutaneous dose (5x10 4 ) of mouse mammary carcinoma tumor cells expressing the A number of reports have demonstrated in different models that CD4 + T cells are important for maintenance and full activation of cytotoxic T cells 25 , induction of an effective memory response 15, 16, 33, 34 and have demonstrated the importance of antigen specific help (both Th1 and Th2 cells) for tumor eradication in vivo 14, 35 . However, the importance of CD4 + T cell help for adoptively transferred gene-modified T cells has not been properly assessed in vivo. In this study we have clearly demonstrated that adoptive transfer of both engineered antigen-specific CD8 + and CD4 + T cells was critical to achieve complete Given that IL-2 has been previously shown to be important for maintaining CD8 + T cell function in vivo 39, 40 , it also remains possible that the provision of IL-2 'help' from transformation in animal models or in patients 4, 5, 9, 26, 44 . Consistent with this we observed no signs of transformation in our long term surviving mice even after tumor rechallenge despite the fact we could clearly detect persistence of our gene-modified cells in both the spleen and peripheral blood. In any case if a problem were to arise with the transfer of genetically modified T cells in patients, a suicide gene strategy involving hsv-tk 45 or the cytoplasmic domain of Fas 46 could be employed. Alternatively the design of new
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One of the striking features of this study was the ability of our gene engineered CD8 + and CD4 + T cells to persist long term and specifically reject a subsequent tumor rechallenge.
This has never been reported previously for adoptively transferred gene-engineered T cells and potentially represents a significant step for application of this type of therapy in the clinic for treatment of not only patients with primary tumors but in cases of tumor relapse where cancer deposits have metastasized to multiple sites. Central to this process was the addition of engineered antigen-specific CD4 + T cells since adoptive transfer of scFv-CD28-ζ engineered CD8 + T cells alone did not persist or mediate a strong anti-tumor effect. Our study supports a large body of work demonstrating the importance of CD4 + T cell help for maintenance of CD8 + T cell function and generation of a recall response 13, 15, 16, 25, 33, 34 .
In this study immunodeficient scid mice were used for T cell transfer experiments due to the immunogenic nature of the human erbB2 target antigen. Although an appropriate model does not exist it would be interesting in future experiments to determine whether CD8 + and CD4 + gene-engineered T cells can persist and induce potent recall responses in an immunocompetent host. Nevertheless the experiments described here using the scid mouse are relevant and can be mimicked in patients by a non-myeloablative regimen involving cyclophosphamide administration. Such regimens are currently being used in patients receiving melanoma-specific T cells which may enhance the therapeutic effect by dampening the immunosuppressive effect of T regulatory cells 28 .
In conclusion, the experiments described in this study 
